# TUMOR HOST RELATIONSHIPS IN HUMAN LYMPHOMAS IN VIVO

> **NIH NIH R01** · STANFORD UNIVERSITY · 1991 · $158,722

## Abstract

Despite major advances in the diagnosis and treatment of human lymphomas,
the clinical behavior for many patients with a particular subtype of
lymphoma remains unpredictable.  Since host immunological mechanisms play
an important role in lymphoma biology, a greater understanding of tumor
host relationships in vivo should help in determining which tumor cell
and host cell features are most important in predicting clinical outcome.
This project will address three major aspects of the tumor host
interaction in vivo: (1) the type and number of effector cells in
lymphoma subgroups, (2) the numbers of tumor cells and proliferating
cells in lymphoma subgroups, (3) the degree of expression of the common
lymphoma-associated proto-oncogene product BCL-2 and of the multidrug
resistance marker "P-glycoprotein" in lymphoma subgroups.  Studies of
sequential biopsies from follicular lymphoma patients may provide
insights in tumor progression/transformation.  Ongoing studies will rely
on frozen section immunohistochemical staining but increasingly will
utilize antibodies reactive with fixation-resistant epitopes.  Recently
developed monoclonal antibodies against cytotoxic cells, memory cells,
homing-associated molecules, and PCNA/Cyclin will be utilized.  Gene
rearrangement studies will also be performed in particular lymphoma
subgroups.  Quantitation of immunostained cells both in frozen and
paraffin sections will employ video densitometry/image analysis.  Methods
will be developed for studying lymphokines and their receptors in
lymphoma cells and host cells.  Increased usage of dual label tissue
section immunohistochemical methods will allow precise identification of
lymphoma cells vs host cell expression of the various biological markers.
Correlations with clinical behavior remain the major focus of this work.
The identification of clinically important immunological parameters may
aid physicians in the selection of a particular treatment modality,
provide the rationale for delay of treatment and may prove useful in
devising experimental treatment strategies.  Long-term goals are to
devise a more reproducible, clinically predictive classification of
lymphomas.  Such an in vivo evaluation of tumor host relationships should
provide valuable insights in lymphoma immunobiology.

## Key facts

- **NIH application ID:** 3171077
- **Project number:** 2R01CA033119-07A1
- **Recipient organization:** STANFORD UNIVERSITY
- **SAM.gov UEI:** HJD6G4D6TJY5
- **Principal Investigator:** ROGER A WARNKE
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1991
- **Award amount:** $158,722
- **Award type:** 2
- **Project period:** 1984-01-01 → 1994-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3171077

## Citation

> US National Institutes of Health, RePORTER application 3171077, TUMOR HOST RELATIONSHIPS IN HUMAN LYMPHOMAS IN VIVO (2R01CA033119-07A1). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3171077. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*